TYK Medicines, Inc
2410.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.34B
Close$
$0.67
80.1% downside
Current Fair Value
80.1% downsideOvervalued by 80.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.34 Billion |
|---|---|
| Enterprise Value | $1.29 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.78 |
| Beta | 2.2 |
| Outstanding Shares | 378,604,014 |
Return
| Return on Equity | -81.43% |
|---|---|
| Return on Assets | -27.65% |
| Return on Invested Capital | -68.33% |
Valuation & Multiples
| P/E Ratio | -5.32 |
|---|---|
| PEG | 6.84 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.65 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About TYK Medicines, Inc
184 employees
CEO: Yusheng Wu TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primar...